06.2021

June 28, 2021
|In Portfolio news
|By Ventac Partners

APIM Therapeutics has presented a poster summarizing results from its on-going first-in-human clinical study with ATX-101 in advanced cancer patients during the Developmental Therapeutics-Molecular Targeted Agents and Tumor Biology Poster Session at the American Society of Clinical Oncology (ASCO) Annual Meeting. A copy of the presented poster can be downloaded here.